
Seurat Therapeutics: Innovating migraine care through research-based medicine from the University of Chicago.
Seurat Therapeutics, founded at the University of Chicago and headquartered in Chicago, Illinois, is a privately held biopharmaceutical company. Their core mission is to transform neurological research breakthroughs into novel medications to treat debilitating nervous system disorders, including migraine headaches, fibromyalgia, chronic pain syndromes, and epileptic seizure disorders. The company leverages years of research from the University of Chicago medical center to innovate migraine care and accelerate the translation of scientific discoveries into life-changing medicine.
Notable affiliated individuals include researchers and scientists from the University of Chicago who have contributed to the foundational research behind Seurat Therapeutics. The company operates out of the Polsky Exchange, a hub for innovation and entrepreneurship. Key achievements include advancing the understanding of neurological disorders and developing potential therapeutic solutions. Seurat Therapeutics has made a significant impact by focusing on conditions that severely affect quality of life, aiming to provide effective treatments where current options are limited.
Seurat Therapeutics' most recent funding round was for $510k (USD) in October 2018.
As of Oct 12, 2018, Seurat Therapeutics has disclosed funding of $1.3M (USD).

Seelos Therapeutics
Chase Therapeutics

Sea Pharmaceuticals

Cerebral Therapeutics

CuraSen Therapeutics
curasen.com
Surmount Bio
Migra Therapeutics

Halia Therapeutics
haliatx.com

Sequitur Health
sequiturhealth.com

Ovid Therapeutics
ovidrx.com

Sequella
sequella.com

Selva Therapeutics
selvarx.com

Selonterra
selonterra.com

ShiraTronics
shiratronics.com

Reservoir Neuroscience
reservoirneuro.com

Secretome Therapeutics

Lysosomal Therapeutics
lysosomaltx.com

Doloromics
doloromics.com

Valted Seq
valtedseq.com

Sequel Pharmaceuticals
sequelpharma.com